Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Recombinant pegylated human FGF21(Tasly Biopharmaceuticals) in Metabolic Dysfunction Associated Steatohepatitis: NCT05655221 Clinical Landscape Report 2026
15 October 2026
NCT05655221 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Pulmovinci in Idiopathic Pulmonary Fibrosis: NCT05657184 Clinical Landscape Report 2026
15 October 2026
NCT05657184 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GSK4172239D in Anemia, Sickle Cell: NCT05660265 Clinical Landscape Report 2026
15 October 2026
NCT05660265 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fitusiran in Hemorrhage: NCT05662319 Clinical Landscape Report 2026
15 October 2026
NCT05662319 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: NCT05662098 Clinical Landscape Report 2026
15 October 2026
NCT05662098 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Moxifloxacin Hydrochloride in Metabolic Dysfunction Associated Steatohepatitis: NCT05668936 Clinical Landscape Report 2026
15 October 2026
NCT05668936 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Methylprednisolone in Idiopathic Pulmonary Fibrosis: NCT05674994 Clinical Landscape Report 2026
15 October 2026
NCT05674994 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
C-188-9 in Idiopathic Pulmonary Fibrosis: NCT05671835 Clinical Landscape Report 2026
15 October 2026
NCT05671835 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Denecimig in Hemophilia A: NCT05685238 Clinical Landscape Report 2026
15 October 2026
NCT05685238 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
OA-235i in Metabolic Dysfunction Associated Steatohepatitis: NCT05680233 Clinical Landscape Report 2026
15 October 2026
NCT05680233 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Denecimig in Hemophilia A: NCT05681845 Clinical Landscape Report 2026
15 October 2026
NCT05681845 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rozanolixizumab in Myasthenia Gravis: NCT05681715 Clinical Landscape Report 2026
15 October 2026
NCT05681715 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.